CSL share price jumps 2% after ASX break as investors zero in on February results
CSL shares closed 2.0% higher at A$183.20 in Sydney, after reaching A$184.62 intraday. Investors are repositioning ahead of half-year results and an interim dividend on Feb. 11, focusing on plasma margins, immunoglobulin sales, and the new drug Andembry. Seqirus remains a concern after the company postponed its spin-off and cut growth forecasts in October.